Season Three of Surfing The NASH Tsunami

S3-E25.6 - Emerging Concepts In NASH: NAFLD Patient Screening, NASH Management

S3-E25.6 – Emerging Concepts In NASH: NAFLD Patient Screening, NASH Management

Surfing the NASH Tsunami shares Dr. Marcelo Kugelmas’s portion of the Madrigal Pharmaceuticals presentation at NAFLD, which covers NAFLD patient screening and diagnostics along with NASH patient management. After this, he answers questions from Roger Green, who then interviews Dr. Naim Alkhouri on disease prevalence and strategies for bringing patient to be tested.

S3-E24.2 - Controversy at the Innovations in NAFLD Care Conference: What is Patient Empowerment In This Situation? S3-E24.2 - Controversy at the Innovations in NAFLD Care Conference: What is Patient Empowerment In This Situation?

S3-E24.2 – Controversy at the Innovations in NAFLD Care Conference: What is Patient Empowerment In This Situation?

Innovations in NAFLD Care conferece co-chair Jeff Lazarus joins Roger Green, Louise Campbell and Jörn Schattenberg to review conference goals and ask whether the agenda and participants put forth a vision of an integrated NAFLD Care pathway. This conversation centers around areas for controversy, including data-driven patient empowerment and what the proper name for this disease should be.

S3-E23.5 - How NAFLD Patient Advocacy Works: Two Key Pieces

S3-E23.5 – How NAFLD Patient Advocacy Works: Two Key Pieces

Patient advocates Achim Kautz and Andrew Scott join the Surfers to discuss the role of NAFLD patient advocacy in the Fatty Liver community. This conversation centers around the importance of taking action locally and enhancing communication across stakeholder groups if we are to keep increasing momentum over time.

S3-E21.3 - Digital Health and Behavioral Support apps in Future NASH Therapies

S3-E21.3 – Digital Health and Behavioral Support apps in Future NASH Therapies

Naim Alkhouri joins Louise Campbell and Roger Green to discuss some of his recent investigator-initiated research projects that focus on future NASH therapies. These include a project evaluating the impact of the behavioral diet app Noom on liver health and a series of others evaluating digital therapeutics and their ability to improve patients’ liver health.

S3-E21.2 - NAFLD Incidence in All Americans and The NASH-Diabetes Link

S3-E21.2 – NAFLD Incidence in All Americans and The NASH-Diabetes Link

Naim Alkhouri joins Louise Campbell and Roger Green to discuss two of his recent publications, one estimating US prevalence based in NHANES data and the other looking at how the treatment choices a physician makes for Type 2 Diabetes can affect long-term NAFLD and NASH incidence.

S3-E16.3 - What a Disease Model tells Us About NASH Patient Management

S3-E16.3 – What a Disease Model tells Us About NASH Patient Management

This episode is Sponsored by Resoundant.
Panelists explore several key questions that have arisen at recent meetings like Liver Connect, including the value of waist circumference measurements, the interplay of NAFLD and alcohol consumption and the definition of a “fast progressor.”

Subscribe for free. New podcasts Wednesday Evening / Thursday Morning.

Apple
Spotify
Google
Stitcher
Buzzsprout
YouTube
SoundCloud